Business Description
Definium Therapeutics Inc
NAICS : 325190
SIC : 3741
ISIN : CA60255C8850
Share Class Description:
DFTX: Ordinary SharesTotal Employee Number:
106Description
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 9.16 | |||||
Equity-to-Asset | 0.7 | |||||
Debt-to-Equity | 0.15 | |||||
Debt-to-EBITDA | -0.18 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 0.8 | |||||
3-Year EPS without NRI Growth Rate | 5 | |||||
3-Year FCF Growth Rate | 3.2 | |||||
3-Year Book Growth Rate | -5.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 36.91 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 96.22 | |||||
9-Day RSI | 92.82 | |||||
14-Day RSI | 89.19 | |||||
3-1 Month Momentum % | 35.29 | |||||
6-1 Month Momentum % | 79.72 | |||||
12-1 Month Momentum % | 269.31 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.69 | |||||
Quick Ratio | 4.69 | |||||
Cash Ratio | 4.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -37.5 | |||||
Shareholder Yield % | -4.48 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -103.28 | |||||
ROA % | -73.37 | |||||
ROIC % | -247.77 | |||||
3-Year ROIIC % | -293.09 | |||||
ROCE % | -86.54 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 17.52 | |||||
Price-to-Tangible-Book | 18.86 | |||||
EV-to-EBIT | -25.5 | |||||
EV-to-EBITDA | -25.5 | |||||
EV-to-Forward-EBITDA | -25.79 | |||||
EV-to-Forward-Revenue | 170.43 | |||||
EV-to-FCF | -40.76 | |||||
| Price-to-Net-Current-Asset-Value | 18.96 | |||||
| Price-to-Net-Cash | 19.51 | |||||
Earnings Yield (Greenblatt) % | -3.92 | |||||
FCF Yield % | -2.32 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:DFTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Definium Therapeutics Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.49 | ||
| Beta | 2.2942 | ||
| 3-Year Sharpe Ratio | 1.15 | ||
| 3-Year Sortino Ratio | 2.52 | ||
| Volatility % | 55.95 | ||
| 14-Day RSI | 89.19 | ||
| 14-Day ATR ($) | 3.048664 | ||
| 20-Day SMA ($) | 29.241 | ||
| 12-1 Month Momentum % | 269.31 | ||
| 52-Week Range ($) | 6.4 - 49.2 | ||
| Shares Outstanding (Mil) | 132.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Definium Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Definium Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 16:30 | In 130 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 129 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-31 16:30 | In 32 days | ||
| Second quarter earnings results for 2026 | 2026-07-31 | In 31 days | ||
| General meeting for 2026 | 2026-06-11 10:00 | 23.24 (+1.62%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 15:10 | 22.86 (-2.93%) | ||
| Guidance call for 2026 | 2026-05-19 08:00 | 20.48 (-2.57%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 16:30 | 23.42 (+4.27%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 23.42 (+4.27%) | ||
| Investor and Analyst Day | 2026-04-22 10:00 | 23.84 (+0.38%) |
Show
Entries
Definium Therapeutics Inc Frequently Asked Questions
What is Definium Therapeutics Inc(DFTX)'s stock price today?
The current price of DFTX is $46.96. The 52 week high of DFTX is $49.20 and 52 week low is $6.40.
When is next earnings date of Definium Therapeutics Inc(DFTX)?
The next earnings date of Definium Therapeutics Inc(DFTX) is 2026-07-31 Est..
Does Definium Therapeutics Inc(DFTX) pay dividends? If so, how much?
Definium Therapeutics Inc(DFTX) does not pay dividend.
Guru Commentaries on NAS:DFTX
No articles.
Press Release
Articles on Definium Therapeutics Inc
No articles.
Headlines
See More- 1
Jun 24, 2026
Definium Therapeutics prices $700M upsized public offering at $34.00 a share
Seeking Alpha • 11:29pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers